LEGACy in the ESMO Executive Board
ESMO members were recently called to vote for the ESMO Executive Board. Included were two members of of the LEGACy Consortium. Now, both have been elected to the ESMO Executive Board. Thank you for your vote of confidence!

ESMO President 2022-2023:
Andrés Cervantes
LEGACy Principal Investigator Andrés Cervantes is the new President-Elect and will serve as the ESMO President in 2022 and 2023. As President he will prioritise education for the Society’s members, and also reinforce ESMO’s leading role in the search for optimal cancer care and prevention through effective advocacy at the policy level. He envisions a global future for the organisation, which has grown internationally in both membership and scientific standing. Cervantes is Head of the Department of Medical Oncology at the University of Valencia, Spain. He currently serves as the Director of Education, with a seat on the Executive Board.
"I am deeply honoured to be given this opportunity to serve ESMO as its future President. As a professional society, we must focus on the best interests of our members: provide access to quality education, support their career development and allow them to serve cancer patients with the highest standard of care. As our organisation expands worldwide, this will also mean taking into account geographical specificities, growing closer to our members and to the national societies in each country, and having a strong voice in health public policy." - Andrés Cervantes

ESMO Director of Education 2020-2021 Florian Lordick
Florian Lordick is Professor of Oncology at the University of Leipzig Medical Centre, Germany, a Partner of the LEGACy Consortium. He is also a member of the Board of Directors of the German Cancer Society (DKG) and is the Coordinator of ESMO’s Faculty for Gastrointestinal Tumours.
"I am delighted to take on the important mission of making our members fit for the future of oncology, ESMO is one of the strongest global networks in this field, with a well-established educational infrastructure. We will forge ahead and scale up our efforts to provide young oncologists and colleagues working in regions with less extensive educational resources with the tools they need to best serve their patients." - Florian Lordick
